journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/30003240/delayed-adoption-of-evidence-based-breast-cancer-surgical-practices-history-repeats-itself
#1
Sara H Javid, Benjamin O Anderson
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003239/beyond-primary-tumor-location-and-ras-braf-mutational-status-as-prognostic-factor-in-stage-iii-colon-cancer
#2
Lisa Salvatore, Fiorella Lombardo, Giampaolo Tortora
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003238/assessment-of-lung-cancer-risk-on-the-basis-of-a-biomarker-panel-of-circulating-proteins
#3
Florence Guida, Nan Sun, Leonidas E Bantis, David C Muller, Peng Li, Ayumu Taguchi, Dilsher Dhillon, Deepali L Kundnani, Nikul J Patel, Qingxiang Yan, Graham Byrnes, Karel G M Moons, Anne Tjønneland, Salvatore Panico, Claudia Agnoli, Paolo Vineis, Domenico Palli, Bas Bueno-de-Mesquita, Petra H Peeters, Antonio Agudo, Jose M Huerta, Miren Dorronsoro, Miguel Rodriguez Barranco, Eva Ardanaz, Ruth C Travis, Karl Smith Byrne, Heiner Boeing, Annika Steffen, Rudolf Kaaks, Anika Hüsing, Antonia Trichopoulou, Pagona Lagiou, Carlo La Vecchia, Gianluca Severi, Marie-Christine Boutron-Ruault, Torkjel M Sandanger, Elisabete Weiderpass Vainio, Therese H Nøst, Kostas Tsilidis, Elio Riboli, Kjell Grankvist, Mikael Johansson, Gary E Goodman, Ziding Feng, Paul Brennan, Mattias Johansson, Samir M Hanash
Importance: There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective: To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants: Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB])...
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003237/surgeon-attitudes-toward-the-omission-of-axillary-dissection-in-early-breast-cancer
#4
Monica Morrow, Reshma Jagsi, M Chandler McLeod, Dean Shumway, Steven J Katz
Importance: The American College of Surgeons Oncology Group (ACOSOG) Z0011 study demonstrated the safety of sentinel node biopsy alone in clinically node-negative women with metastases in 1 or 2 sentinel nodes treated with breast conservation. Little is known about surgeon perspectives regarding when axillary lymph node dissection (ALND) can be omitted. Objectives: To determine surgeon acceptance of ACOSOG Z0011 findings, identify characteristics associated with acceptance of ACOSOG Z0011 results, and examine the association between acceptance of the Society of Surgical Oncology and American Society for Radiation Oncology negative margin of no ink on tumor and surgeon preference for ALND...
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003235/causes-of-death-and-conditional-survival-estimates-of-medium-and-long-term-survivors-of-pancreatic-adenocarcinoma
#5
Douglas S Swords, Sean J Mulvihill, Matthew A Firpo, Courtney L Scaife
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003234/management-of-relapsed-and-refractory-hodgkin-lymphoma-in-2018
#6
Sarah C Rutherford, John P Leonard
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003233/association-of-second-allogeneic-hematopoietic-cell-transplant-vs-donor-lymphocyte-infusion-with-overall-survival-in-patients-with-acute-myeloid-leukemia-relapse
#7
Mohamed A Kharfan-Dabaja, Myriam Labopin, Emmanuelle Polge, Taiga Nishihori, Ali Bazarbachi, Jürgen Finke, Michael Stadler, Gerhard Ehninger, Bruno Lioure, Nicolaas Schaap, Boris Afanasyev, Moshe Yeshurun, Cecilia Isaksson, Johan Maertens, Yves Chalandon, Christoph Schmid, Arnon Nagler, Mohamad Mohty
Importance: The optimal treatment approach to patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) remains elusive. No randomized clinical trial comparing survival outcomes of a second allo-HCT (allo-HCT2) vs donor lymphocyte infusion (DLI) has been conducted to date. Objective: To compare overall survival (OS) after an allo-HCT2 or DLI in relapsed AML after a first allo-HCT. Design, Setting, and Participants: A retrospective registry study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation involving 418 adults who received an allo-HCT2 (n = 137) or DLI (n = 281) for postallograft-relapsed AML...
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003231/conditional-survival-as-a-pragmatic-resource-for-cancer-survivors-and-health-care-professionals
#8
Charles R Thomas
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003230/optimal-multimodal-treatment-for-desmoplastic-small-round-cell-tumors
#9
Olivier Mir, Julien Adam, Charles Honoré
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003229/optimal-multimodal-treatment-for-desmoplastic-small-round-cell-tumors-reply
#10
Aung Myint Tun, Wai Lin Thein, Elizabeth Guevara
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30003228/beyond-primary-tumor-location-and-ras-braf-mutational-status-as-prognostic-factor-in-stage-iii-colon-cancer-reply
#11
Julien Taieb
No abstract text is available yet for this article.
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978217/expert-review-of-breast-pathology-in-borderline-lesions-a-chance-to-reduce-overdiagnosis-and-overtreatment
#12
Francesco Sardanelli, Rubina M Trimboli, Tibor Tot
No abstract text is available yet for this article.
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978216/safety-and-efficacy-of-bind-014-a-docetaxel-nanoparticle-targeting-prostate-specific-membrane-antigen-for-patients-with-metastatic-castration-resistant-prostate-cancer-a-phase-2-clinical-trial
#13
Karen A Autio, Robert Dreicer, Justine Anderson, Jorge A Garcia, Ajjai Alva, Lowell L Hart, Matthew I Milowsky, Edwin M Posadas, Charles J Ryan, Ryon P Graf, Ryan Dittamore, Nicole A Schreiber, Jason M Summa, Hagop Youssoufian, Michael J Morris, Howard I Scher
Importance: Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has implications for patient selection and disease monitoring. Objective: To determine the safety and efficacy of BIND-014, a PSMA-directed docetaxel-containing nanoparticle, in patients with metastatic castration-resistant prostate cancer (mCRPC)...
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978199/broadening-the-view-of-germline-mutations-in-kidney-cancer
#14
Patrick G Pilié, Kathleen A Cooney
No abstract text is available yet for this article.
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978198/clarification-of-the-fda-accelerated-agnostic-approval-of-pembrolizumab-and-the-opportunities-arising-from-the-required-confirmatory-studies
#15
https://www.readbyqxmd.com/read/29978197/clarification-of-the-fda-accelerated-agnostic-approval-of-pembrolizumab-and-the-opportunities-arising-from-the-required-confirmatory-studies-reply
#16
Vinay Prasad, Victoria Kaestner, Sham Mailankody
No abstract text is available yet for this article.
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978191/implementation-challenges-for-risk-stratified-screening-in-the-era-of-precision-medicine
#17
Megan C Roberts
No abstract text is available yet for this article.
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978189/cost-effectiveness-and-benefit-to-harm-ratio-of-risk-stratified-screening-for-breast-cancer-a-life-table-model
#18
Nora Pashayan, Steve Morris, Fiona J Gilbert, Paul D P Pharoah
Importance: The age-based or "one-size-fits-all" breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis. Identifying risk-stratified screening strategies with a more favorable ratio of overdiagnoses to breast cancer deaths prevented would improve the quality of life of women and save resources. Objective: To assess the benefit-to-harm ratio and the cost-effectiveness of risk-stratified breast screening programs compared with a standard age-based screening program and no screening...
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978187/prevalence-of-germline-mutations-in-cancer-susceptibility-genes-in-patients-with-advanced-renal-cell-carcinoma
#19
Maria I Carlo, Semanti Mukherjee, Diana Mandelker, Joseph Vijai, Yelena Kemel, Liying Zhang, Andrea Knezevic, Sujata Patil, Ozge Ceyhan-Birsoy, Kuo-Cheng Huang, Almedina Redzematovic, Devyn T Coskey, Carolyn Stewart, Nisha Pradhan, Angela G Arnold, A Ari Hakimi, Ying-Bei Chen, Jonathan A Coleman, David M Hyman, Marc Ladanyi, Karen A Cadoo, Michael F Walsh, Zsofia K Stadler, Chung-Han Lee, Darren R Feldman, Martin H Voss, Mark Robson, Robert J Motzer, Kenneth Offit
Importance: Identification of patients with hereditary renal cell carcinoma (RCC) is important for cancer screening and, in patients with advanced disease, for guiding treatment. The prevalence of cancer-related germline mutations in patients with advanced RCC and the phenotypes associated with some rare mutations are unknown. Objectives: To examine the prevalence of germline mutations in both known RCC predisposition genes and other cancer-associated genes and to identify clinical and pathologic factors associated with germline mutations...
July 5, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29978183/paclitaxel-and-pazopanib-in-ovarian-cancer-reply
#20
Debra L Richardson, Robert L Coleman, Michael W Sill
No abstract text is available yet for this article.
July 5, 2018: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"